Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    riociguat scleroderma

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02283762
Recruitment Status : Completed
First Posted : November 5, 2014
Results First Posted : January 25, 2019
Last Update Posted : February 5, 2020
Sponsor:
Information provided by (Responsible Party):
Bayer

Study Type Interventional
Study Design Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition Scleroderma, Systemic
Interventions Drug: Riociguat (Adempas, BAY63-2521)
Drug: Placebo
Enrollment 121
Recruitment Details The study was conducted between 15 January 2015 (first patient first visit) and 28 March 2019 (last patient last visit). The Main Treatment Phase has been conducted between 15 Jan 2015 (first subject first visit) and 03 Jan 2018 (last subject last visit for the main treatment phase).
Pre-assignment Details

139 patients were screened in 60 study centers in 15 countries worldwide. 121 patients of 139 patients were randomized and treated with at least one dose of study medication.

88 of the 121 randomized patients completed the treatment phase, of whom 87 entered the long term extension (LTE) phase.

Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period. Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Period Title: Main Treatment Phase (MT)
Started 60 61
Completed 42 46
Not Completed 18 15
Reason Not Completed
Adverse Event             9             9
Lack of Efficacy             1             0
Physician Decision             1             1
Pregnancy             0             1
Withdrawal by Subject             7             4
Period Title: Long-term Extension Phase (LTE)
Started 42 45 [1]
Completed 32 31
Not Completed 10 14
Reason Not Completed
Adverse Event             2             6
Lack of Efficacy             1             1
Study terminated at site             1             0
Withdrawal by Subject             4             3
Protocol Violation             1             1
Lost to Follow-up             0             1
Physician Decision             1             2
[1]
Of the 46 patients who completed the main treatment phase, 1 patient did not enter the LTE phase
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo Total
Hide Arm/Group Description Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period. Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period. Total of all reporting groups
Overall Number of Baseline Participants 60 61 121
Hide Baseline Analysis Population Description
[Not Specified]
Age, Continuous  
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 60 participants 61 participants 121 participants
51.9  (11.5) 49.5  (12.9) 50.7  (12.2)
Sex: Female, Male  
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 60 participants 61 participants 121 participants
Female
47
  78.3%
45
  73.8%
92
  76.0%
Male
13
  21.7%
16
  26.2%
29
  24.0%
Race/Ethnicity, Customized  
Measure Type: Number
Unit of measure:  Participants
Number Analyzed 60 participants 61 participants 121 participants
White 43 46 89
Black 2 3 5
Asian 12 12 24
Native Hawaiian or other pacific islander 1 0 1
Not Hispanic or Latino 59 58 117
Modified Rodnan skin score (mRSS)   [1] 
Mean (Standard Deviation)
Unit of measure:  Score on a scale
Number Analyzed 60 participants 61 participants 121 participants
16.9  (3.4) 16.7  (4.1) 16.8  (3.7)
[1]
Measure Description: The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of systemic sclerosis (SSc).
Forced vital capacity (FVC) percent predicted   [1] 
Mean (Standard Deviation)
Unit of measure:  FVC percent predicted
Number Analyzed 60 participants 61 participants 121 participants
90.743  (18.523) 94.823  (17.034) 92.800  (17.832)
[1]
Measure Description: Pulmonary function tests included forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO). FVC percent predicted was reported.
1.Primary Outcome
Title Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52
Hide Description The mRSS is a validated physical examination method for estimating skin thickness. It correlates with biopsy measures of collagen in the dermis and reflects prognosis and visceral involvement, especially in early disease. It is scored on 0 (normal) to 3+ (severe induration) ordinal scales over 17 body areas, with a maximum score of 51 (higher score means worse situation) and is used to categorize severity of SSc. A decrease in the mean change of mRSS shows mRSS improved.
Time Frame Baseline to week 52
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS: all participants randomized and treated with study medication) with evaluable data for this outcome measure.
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 57 52
Mean (Standard Deviation)
Unit of Measure: score on a scale
-2.088  (5.658) -0.769  (8.243)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments [Not Specified]
Statistical Test of Hypothesis P-Value 0.0815
Comments [Not Specified]
Method MMRM (Method 1)
Comments [Not Specified]
Method of Estimation Estimation Parameter Difference of LS means
Estimated Value -2.34
Confidence Interval (2-Sided) 95%
-4.99 to 0.30
Estimation Comments [Not Specified]
2.Secondary Outcome
Title CRISS (American College of Rheumatology Composite Response Index for Clinical Trials) at Week 52 Reported as Number of Participants With a CRISS Probability >=0.60 or <0.60 From Baseline to Week 52
Hide Description CRISS forms a composite response index consisting of SSc-related organ involvement and the following five variables: mRSS, FVC percent predicted, physician's and patient's global assessments, and HAQ-DI score (from SHAQ patient-reported outcome). The resulting index is a 2-step process that captures clinically meaningful worsening of internal organ involvement and the core variables that show change. Patients for whom the predicted CRISS probability was ≥ 0.60 were considered improved, while patients for whom the predicted probability was < 0.60 were considered not improved.
Time Frame Week 52
Hide Outcome Measure Data
Hide Analysis Population Description
Full analysis set (FAS)
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 60 61
Measure Type: Count of Participants
Unit of Measure: Participants
CRISS probability ≥ 0.60
11
  18.3%
11
  18.0%
CRISS probability < 0.60
49
  81.7%
50
  82.0%
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments [Not Specified]
Type of Statistical Test Superiority
Comments The pre-specified test was for superiority but ONLY if the primary endpoint and secondary endpoints were meeting statistical significance (hierarchical testing).
Statistical Test of Hypothesis P-Value 0.9770
Comments [Not Specified]
Method Mantel Haenszel
Comments [Not Specified]
Method of Estimation Estimation Parameter %
Estimated Value 0.2
Confidence Interval (2-Sided) 95%
-13.68 to 14.09
Estimation Comments [Not Specified]
3.Secondary Outcome
Title Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score to Week 52
Hide Description The HAQ-DI is a composite measure from which a 'Standard Disability Index' score can be computed to assess a patient's disability level. Generally, a score of 0-1 represents mild to moderate difficulty, 1-2 moderate to severe disability and 2-3 severe to very severe disability. The HAQ-DI comprises 20 items that assess patient abilities across 8 functional activities: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item is rated on a 4-point scale: 0=Without ANY difficulty, 1=With SOME difficulty, 2=With MUCH difficulty, 3=UNABLE to do. The 8 scores of the 8 sections are summed and divided by 8. In the event that one section is not completed by a subject then the summed score would be divided by 7. The final overall HAQ-DI score ranges from 0 to 3 and positive change indicates worse health-related quality of life (HRQoL).
Time Frame Baseline to week 52
Hide Outcome Measure Data
Hide Analysis Population Description
FAS with evaluable data for this outcome measure.
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 60 61
Mean (Standard Deviation)
Unit of Measure: score on a scale
Baseline Number Analyzed 60 participants 61 participants
0.888  (0.665) 0.693  (0.688)
Change from baseline Number Analyzed 56 participants 52 participants
0.054  (0.381) 0.127  (0.418)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments change from baseline
Type of Statistical Test Superiority
Comments The pre-specified test was for superiority but ONLY if the primary endpoint and secondary endpoints were meeting statistical significance (hierarchical testing).
Statistical Test of Hypothesis P-Value 0.3529
Comments [Not Specified]
Method MMRM (Method 1)
Comments [Not Specified]
Method of Estimation Estimation Parameter Difference in LS means
Estimated Value -0.07
Confidence Interval (2-Sided) 95%
-0.23 to 0.08
Estimation Comments [Not Specified]
4.Secondary Outcome
Title Change From Baseline in Patient's Global Assessment Score to Week 52
Hide Description The patient's global assessments (a self-report) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the patient's global assessments score indicates worsening.
Time Frame Baseline to week 52
Hide Outcome Measure Data
Hide Analysis Population Description
FAS with evaluable data for this outcome measure.
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 60 61
Mean (Standard Deviation)
Unit of Measure: score on a scale
Baseline Number Analyzed 60 participants 61 participants
3.933  (2.497) 3.770  (2.341)
Change from baseline Number Analyzed 45 participants 46 participants
0.689  (2.745) -0.022  (2.226)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments Change from baseline
Type of Statistical Test Superiority
Comments The pre-specified test was for superiority but ONLY if the primary endpoint and secondary endpoints were meeting statistical significance (hierarchical testing).
Statistical Test of Hypothesis P-Value 0.0887
Comments [Not Specified]
Method MMRM (Method 1)
Comments [Not Specified]
Method of Estimation Estimation Parameter Difference in LS means
Estimated Value 0.79
Confidence Interval (2-Sided) 95%
-0.12 to 1.69
Estimation Comments [Not Specified]
5.Secondary Outcome
Title Change From Baseline in Physician's Global Assessment Score to Week 52
Hide Description The physician's global assessments (reported by the physician) quantified the overall disease activity or severity of SSc, with scores ranging from 0 (good) to 10 (worse). Positive change in the physician's global assessments score indicates worsening.
Time Frame Baseline to week 52
Hide Outcome Measure Data
Hide Analysis Population Description
FAS with evaluable data for this outcome measure.
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 60 61
Mean (Standard Deviation)
Unit of Measure: score on a scale
Baseline Number Analyzed 60 participants 61 participants
4.333  (2.105) 4.016  (2.004)
Change from baseline Number Analyzed 45 participants 47 participants
-0.067  (2.157) -0.745  (2.090)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments Change from baseline
Type of Statistical Test Superiority
Comments The pre-specified test was for superiority but ONLY if the primary endpoint and secondary endpoints were meeting statistical significance (hierarchical testing).
Statistical Test of Hypothesis P-Value 0.0241
Comments [Not Specified]
Method MMRM (Method 1)
Comments [Not Specified]
Method of Estimation Estimation Parameter Difference in LS means
Estimated Value 0.83
Confidence Interval (2-Sided) 95%
0.11 to 1.54
Estimation Comments [Not Specified]
6.Secondary Outcome
Title Change From Baseline in Forced Vital Capacity (FVC) Percent Predicted to Week 52
Hide Description Negative change in FVC percent predicted indicates worsening.
Time Frame Baseline to week 52
Hide Outcome Measure Data
Hide Analysis Population Description
FAS with evaluable data for this outcome measure.
Arm/Group Title Riociguat (Adempas, BAY63-2521) Placebo
Hide Arm/Group Description:
Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period.
Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
Overall Number of Participants Analyzed 55 51
Mean (Standard Deviation)
Unit of Measure: FVC percent predicted
-2.376  (7.515) -2.945  (9.727)
Hide Statistical Analysis 1
Statistical Analysis Overview Comparison Group Selection Riociguat (Adempas, BAY63-2521), Placebo
Comments change from baseline
Type of Statistical Test Superiority
Comments The pre-specified test was for superiority but ONLY if the primary endpoint and secondary endpoints were meeting statistical significance (hierarchical testing).
Statistical Test of Hypothesis P-Value 0.9010
Comments [Not Specified]
Method MMRM (Method 1)
Comments [Not Specified]
Method of Estimation Estimation Parameter Difference in LS means
Estimated Value -0.20
Confidence Interval (2-Sided) 95%
-3.40 to 3.00
Estimation Comments [Not Specified]
Time Frame From first application of study drug up to 2 days after end of treatment with study drug, up to 4 years.
Adverse Event Reporting Description All 42 patients who completed the main treatment phase from the riociguat group entered the LTE phase and continued to receive riociguat. This group is referred in the LTE phase to “riociguat-riociguat group”. One of the 46 patients from the placebo group did not enter the LTE phase. This group is referred to “placebo-riociguat group”.
 
Arm/Group Title Riociguat-Riociguat (LTE Phase) Placebo-Riociguat (LTE Phase) Riociguat (Main Treatment Phase) Placebo (Main Treatment Phase)
Hide Arm/Group Description Main treatment phase: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting from Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period. Main treatment phase: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting from Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period. Main treatment phase of 52 weeks: participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a-titration period of up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received sham-titration in a dose-titration period of up to 10 weeks followed by a maintenance period. Main treatment phase of 52 weeks: participants received matching placebo tablets to riociguat as sham-titration in a dose-titration period up to 10 weeks and a maintenance period of up to 42 weeks. Long-term extension phase: starting after the completion of the Main Treatment Phase in Week 52, participants received increasing doses of riociguat by 0.5 mg every 2 weeks up to 2.5 mg 3 times a day (TID) in a dose-titration period of up to 10 weeks followed by a maintenance period.
All-Cause Mortality
Riociguat-Riociguat (LTE Phase) Placebo-Riociguat (LTE Phase) Riociguat (Main Treatment Phase) Placebo (Main Treatment Phase)
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   0/42 (0.00%)      0/45 (0.00%)      1/60 (1.67%)      1/61 (1.64%)    
Hide Serious Adverse Events
Riociguat-Riociguat (LTE Phase) Placebo-Riociguat (LTE Phase) Riociguat (Main Treatment Phase) Placebo (Main Treatment Phase)
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   10/42 (23.81%)      11/45 (24.44%)      9/60 (15.00%)      15/61 (24.59%)    
Blood and lymphatic system disorders         
Anaemia * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 1/61 (1.64%)  1
Febrile neutropenia * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Thrombocytopenia * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Cardiac disorders         
Angina pectoris * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 1/61 (1.64%)  1
Atrial fibrillation * 1  1/42 (2.38%)  2 0/45 (0.00%)  0 1/60 (1.67%)  2 0/61 (0.00%)  0
Left ventricular failure * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Pericarditis * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 2/61 (3.28%)  2
Ventricular tachycardia * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 1/61 (1.64%)  1
Cardiac failure * 1  0/42 (0.00%)  0 1/45 (2.22%)  2 0/60 (0.00%)  0 0/61 (0.00%)  0
Extrasystoles * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Tachycardia * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Gastrointestinal disorders         
Abdominal pain * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 1/60 (1.67%)  3 0/61 (0.00%)  0
Gastric haemorrhage * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Gastrooesophageal reflux disease * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Intestinal pseudo-obstruction * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Nausea * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Vomiting * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Abdominal distension * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Diverticulum intestinal * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Haematemesis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Ileus * 1  0/42 (0.00%)  0 1/45 (2.22%)  3 0/60 (0.00%)  0 0/61 (0.00%)  0
Intestinal obstruction * 1  1/42 (2.38%)  2 1/45 (2.22%)  2 0/60 (0.00%)  0 0/61 (0.00%)  0
Subileus * 1  0/42 (0.00%)  0 1/45 (2.22%)  2 0/60 (0.00%)  0 0/61 (0.00%)  0
General disorders         
Inflammation * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Infections and infestations         
Infected skin ulcer * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Pneumonia * 1  0/42 (0.00%)  0 1/45 (2.22%)  2 1/60 (1.67%)  1 2/61 (3.28%)  2
Lung infection * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Appendicitis * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Gastroenteritis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Localised infection * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Postoperative wound infection * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Salpingitis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Sepsis * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Staphylococcal infection * 1  1/42 (2.38%)  2 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Bursitis infective * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Device related sepsis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Medical device site joint infection * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Injury, poisoning and procedural complications         
Exposure during pregnancy * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Hand fracture * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Investigations         
Ultrasound kidney abnormal * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Metabolism and nutrition disorders         
Fluid overload * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Musculoskeletal and connective tissue disorders         
Osteolysis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Pain in extremity * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Scleroderma * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Musculoskeletal discomfort * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Cervical spinal stenosis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Spinal osteoarthritis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Chondropathy * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Systemic scleroderma * 1  0/42 (0.00%)  0 2/45 (4.44%)  6 0/60 (0.00%)  0 0/61 (0.00%)  0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)         
Acute myeloid leukaemia * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Adenocarcinoma gastric * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Ovarian cancer * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Intraductal proliferative breast lesion * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Tongue neoplasm malignant stage unspecified * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Nervous system disorders         
Cerebellar infarction * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Syncope * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Renal and urinary disorders         
Scleroderma renal crisis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Acute kidney injury * 1  0/42 (0.00%)  0 1/45 (2.22%)  1 0/60 (0.00%)  0 0/61 (0.00%)  0
Respiratory, thoracic and mediastinal disorders         
Acute pulmonary oedema * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Dyspnoea * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 0/61 (0.00%)  0
Acute respiratory distress syndrome * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Epistaxis * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Skin and subcutaneous tissue disorders         
Skin ulcer * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Surgical and medical procedures         
Prophylaxis * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
Rhinoplasty * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Large intestinal polypectomy * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
Vascular disorders         
Raynaud's phenomenon * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 1/60 (1.67%)  1 1/61 (1.64%)  1
Hypertension * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 0/60 (0.00%)  0 0/61 (0.00%)  0
1
Term from vocabulary, MedDRA (20.1)
*
Indicates events were collected by non-systematic assessment
Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
Riociguat-Riociguat (LTE Phase) Placebo-Riociguat (LTE Phase) Riociguat (Main Treatment Phase) Placebo (Main Treatment Phase)
Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events Affected / at Risk (%) # Events
Total   38/42 (90.48%)      39/45 (86.67%)      55/60 (91.67%)      49/61 (80.33%)    
Blood and lymphatic system disorders         
Anaemia * 1  3/42 (7.14%)  3 4/45 (8.89%)  4 2/60 (3.33%)  2 3/61 (4.92%)  4
Iron deficiency anaemia * 1  3/42 (7.14%)  3 0/45 (0.00%)  0 1/60 (1.67%)  1 1/61 (1.64%)  1
Cardiac disorders         
Palpitations * 1  3/42 (7.14%)  3 1/45 (2.22%)  1 8/60 (13.33%)  8 3/61 (4.92%)  3
Gastrointestinal disorders         
Abdominal distension * 1  0/42 (0.00%)  0 4/45 (8.89%)  6 4/60 (6.67%)  5 1/61 (1.64%)  1
Abdominal pain * 1  3/42 (7.14%)  3 1/45 (2.22%)  3 2/60 (3.33%)  2 5/61 (8.20%)  5
Constipation * 1  4/42 (9.52%)  5 2/45 (4.44%)  2 3/60 (5.00%)  3 4/61 (6.56%)  4
Diarrhoea * 1  5/42 (11.90%)  11 8/45 (17.78%)  23 10/60 (16.67%)  15 8/61 (13.11%)  11
Dry mouth * 1  1/42 (2.38%)  1 2/45 (4.44%)  2 4/60 (6.67%)  4 1/61 (1.64%)  1
Dyspepsia * 1  1/42 (2.38%)  1 2/45 (4.44%)  3 7/60 (11.67%)  7 2/61 (3.28%)  2
Dysphagia * 1  1/42 (2.38%)  1 1/45 (2.22%)  1 6/60 (10.00%)  7 1/61 (1.64%)  1
Gastrooesophageal reflux disease * 1  7/42 (16.67%)  7 8/45 (17.78%)  8 15/60 (25.00%)  16 7/61 (11.48%)  7
Nausea * 1  2/42 (4.76%)  5 6/45 (13.33%)  7 7/60 (11.67%)  9 6/61 (9.84%)  6
Vomiting * 1  7/42 (16.67%)  11 4/45 (8.89%)  14 8/60 (13.33%)  14 6/61 (9.84%)  8
Mouth ulceration * 1  3/42 (7.14%)  4 0/45 (0.00%)  0 0/60 (0.00%)  0 1/61 (1.64%)  1
General disorders         
Asthenia * 1  2/42 (4.76%)  2 1/45 (2.22%)  1 3/60 (5.00%)  6 3/61 (4.92%)  4
Fatigue * 1  0/42 (0.00%)  0 4/45 (8.89%)  4 7/60 (11.67%)  7 6/61 (9.84%)  7
Oedema peripheral * 1  1/42 (2.38%)  1 3/45 (6.67%)  3 6/60 (10.00%)  7 2/61 (3.28%)  2
Pain * 1  1/42 (2.38%)  1 1/45 (2.22%)  1 3/60 (5.00%)  4 0/61 (0.00%)  0
Pyrexia * 1  1/42 (2.38%)  1 1/45 (2.22%)  1 2/60 (3.33%)  2 4/61 (6.56%)  4
Peripheral swelling * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 5/60 (8.33%)  6 5/61 (8.20%)  5
Infections and infestations         
Bronchitis * 1  5/42 (11.90%)  6 0/45 (0.00%)  0 3/60 (5.00%)  3 1/61 (1.64%)  1
Nasopharyngitis * 1  11/42 (26.19%)  13 10/45 (22.22%)  10 5/60 (8.33%)  7 5/61 (8.20%)  8
Upper respiratory tract infection * 1  7/42 (16.67%)  10 6/45 (13.33%)  7 4/60 (6.67%)  5 8/61 (13.11%)  10
Urinary tract infection * 1  2/42 (4.76%)  7 3/45 (6.67%)  4 4/60 (6.67%)  5 2/61 (3.28%)  2
Gastroenteritis * 1  2/42 (4.76%)  2 5/45 (11.11%)  6 1/60 (1.67%)  1 2/61 (3.28%)  2
Influenza * 1  3/42 (7.14%)  3 4/45 (8.89%)  5 2/60 (3.33%)  2 0/61 (0.00%)  0
Pneumonia * 1  3/42 (7.14%)  3 0/45 (0.00%)  0 1/60 (1.67%)  2 2/61 (3.28%)  2
Injury, poisoning and procedural complications         
Contusion * 1  2/42 (4.76%)  2 3/45 (6.67%)  3 1/60 (1.67%)  1 0/61 (0.00%)  0
Metabolism and nutrition disorders         
Hypokalaemia * 1  0/42 (0.00%)  0 3/45 (6.67%)  4 0/60 (0.00%)  0 1/61 (1.64%)  2
Musculoskeletal and connective tissue disorders         
Arthralgia * 1  4/42 (9.52%)  5 6/45 (13.33%)  6 12/60 (20.00%)  14 8/61 (13.11%)  9
Back pain * 1  2/42 (4.76%)  2 1/45 (2.22%)  1 3/60 (5.00%)  3 4/61 (6.56%)  4
Muscle spasms * 1  2/42 (4.76%)  3 2/45 (4.44%)  2 4/60 (6.67%)  6 0/61 (0.00%)  0
Pain in extremity * 1  4/42 (9.52%)  4 2/45 (4.44%)  3 4/60 (6.67%)  6 2/61 (3.28%)  2
Bursitis * 1  2/42 (4.76%)  3 3/45 (6.67%)  3 2/60 (3.33%)  2 0/61 (0.00%)  0
Myalgia * 1  4/42 (9.52%)  5 2/45 (4.44%)  2 1/60 (1.67%)  1 3/61 (4.92%)  3
Nervous system disorders         
Dizziness * 1  3/42 (7.14%)  3 6/45 (13.33%)  7 13/60 (21.67%)  21 7/61 (11.48%)  7
Headache * 1  3/42 (7.14%)  4 4/45 (8.89%)  4 11/60 (18.33%)  12 12/61 (19.67%)  16
Paraesthesia * 1  0/42 (0.00%)  0 2/45 (4.44%)  2 1/60 (1.67%)  1 4/61 (6.56%)  5
Psychiatric disorders         
Insomnia * 1  2/42 (4.76%)  2 0/45 (0.00%)  0 3/60 (5.00%)  3 2/61 (3.28%)  2
Respiratory, thoracic and mediastinal disorders         
Cough * 1  6/42 (14.29%)  6 3/45 (6.67%)  4 9/60 (15.00%)  9 5/61 (8.20%)  5
Dyspnoea * 1  3/42 (7.14%)  3 3/45 (6.67%)  4 8/60 (13.33%)  9 5/61 (8.20%)  6
Epistaxis * 1  2/42 (4.76%)  2 1/45 (2.22%)  1 4/60 (6.67%)  5 2/61 (3.28%)  2
Interstitial lung disease * 1  5/42 (11.90%)  6 5/45 (11.11%)  5 4/60 (6.67%)  4 2/61 (3.28%)  2
Skin and subcutaneous tissue disorders         
Eczema * 1  2/42 (4.76%)  2 0/45 (0.00%)  0 0/60 (0.00%)  0 4/61 (6.56%)  4
Erythema * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 3/60 (5.00%)  4 0/61 (0.00%)  0
Pruritus * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 5/60 (8.33%)  6 5/61 (8.20%)  9
Rash * 1  1/42 (2.38%)  1 0/45 (0.00%)  0 3/60 (5.00%)  4 2/61 (3.28%)  2
Skin ulcer * 1  6/42 (14.29%)  7 4/45 (8.89%)  4 4/60 (6.67%)  4 7/61 (11.48%)  9
Urticaria * 1  0/42 (0.00%)  0 3/45 (6.67%)  4 2/60 (3.33%)  2 0/61 (0.00%)  0
Vascular disorders         
Hypertension * 1  0/42 (0.00%)  0 0/45 (0.00%)  0 0/60 (0.00%)  0 4/61 (6.56%)  4
Hypotension * 1  5/42 (11.90%)  6 7/45 (15.56%)  9 7/60 (11.67%)  7 4/61 (6.56%)  4
1
Term from vocabulary, MedDRA (20.1)
*
Indicates events were collected by non-systematic assessment
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Any proposed publications should be sent to Bayer for review at least 40 days before forwarding to any person that is not bound by the confidentially obligations. Bayer may request delay of publication for no more than 120 days to allow for filing Patent Applications (if applicable). No publication of single center data should be done prior to publication of multicenter data.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Therapeutic Area Head
Organization: Bayer
Phone: +1 888-8422937
EMail: clinical-trials-contact@bayer.com
Layout table for additonal information
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT02283762    
Other Study ID Numbers: 16277
2014-001353-16 ( EudraCT Number )
First Submitted: November 3, 2014
First Posted: November 5, 2014
Results First Submitted: December 13, 2018
Results First Posted: January 25, 2019
Last Update Posted: February 5, 2020